The IPO Buzz: French Biotech Abivax Preps for NASDAQ

Abivax S.A., a French biotech whose ulcerative colitis drug candidate is in Phase 3 clinical trials, aims to raise $250 million in its NASDAQ uplisting this week. Abivax (ABVX proposed) launched its U.S. public offering of 18.68 million American Depositary Shares (ADS) on Monday (Oct. 16, 2023) by disclosing terms and starting its roadshow. The […]

October 17, 2023 Read More

The IPO Buzz: Birkenstock on the IPO Runway

Birkenstock is getting ready to walk the IPO runway. Wall Street hopes that this will be a victory stroll for Birkenstock Holding plc (BIRK proposed) – the British parent of the iconic German sandal company. The sandals’ design heritage goes back to 1774. “Barbie” wore a pair of light pink leather Birkenstock Arizona slides in […]

October 9, 2023 Read More

The IPO Buzz: Birkenstock Sets Terms for $1.5 Billion IPO

Off to the races in October: Birkenstock Holding Limited (BIRK proposed), the parent of the iconic German sandal company, unveiled the terms early today for its $1.5 billion IPO: 32.26 million ordinary shares at a price range of $44.00 to $49.00, according to an F-1/A filing dated Oct. 2, 2023. The company is offering 10.75 […]

October 2, 2023 Read More